Skip to content

Advertisement

  • Research
  • Open Access

Myeloid-specific TAK1 deletion results in reduced brain monocyte infiltration and improved outcomes after stroke

  • 1,
  • 1,
  • 1,
  • 1,
  • 1,
  • 2,
  • and
  • 1, 3Email author
Journal of Neuroinflammation201815:148

https://doi.org/10.1186/s12974-018-1188-3

  • Received: 2 January 2018
  • Accepted: 3 May 2018
  • Published:

Abstract

Background

Activation of transforming growth factor-β-activated kinase 1 (TAK1) occurs after stroke and leads to an exacerbation of brain injury. TAK1 is involved in innate and adaptive immune responses, but it has divergent inflammatory effects that are dependent on the cell type in which it is activated. There is a robust infiltration of myeloid cells after stroke; however, the contribution of myeloid TAK1 to cerebral ischemia is currently unknown. We hypothesized that myeloid-specific deletion of TAK1 would protect against ischemic brain injury.

Methods

Myeloid TAK1ΔM and wild-type (WT) mice were subjected to middle cerebral artery occlusion (MCAo). Brain-infiltrating and splenic immune cells were evaluated at 3 days after stroke. Assessment of infarct size and behavioral deficits were performed on days 3 and 7 post-stroke.

Results

Infarcts were significantly smaller in TAK1ΔM mice (p < 0.01), and behavioral deficits were less severe despite equivalent reduction in cerebral blood flow. Flow cytometry demonstrated an increase in the frequency of splenic monocytes and neutrophils (p < 0.05) and a decrease in splenic CD3+ T (p < 0.01) and CD19+ B (p = 0.06) cells in TAK1ΔM mice compared to WT at baseline. Three days after stroke, a significant increase in the number of brain-infiltrating immune cell was observed in both TAK1ΔM (p < 0.05) and WT (p < 0.001) mice compared to their respective shams. However, there was a significant decrease in the infiltrating CD45hi immune cell counts (p < 0.05), with a pronounced reduction in infiltrating monocytes (p < 0.001) in TAK1ΔM after stroke compared to WT stroke mice. Additionally, a significant reduction in CD49d+ monocytes was seen in the brains of TAK1ΔM stroke mice compared to wild-type mice. Importantly, TAK1ΔM MCAo mice had smaller infarcts and improved behavioral outcomes at day 7 post-stroke.

Conclusion

Our results showed that deletion of myeloid TAK1 resulted in smaller infarcts and improved functional outcomes at the peak of inflammation (day 3) and a reduction in brain-infiltrating immune cells that were primarily monocytes. Myeloid TAK1 deletion was also protective at 7 days post MCAo, reflecting a detrimental role of myeloid TAK1 in the progression of ischemic injury.

Keywords

  • Ischemic stroke
  • Monocytes
  • Neutrophils
  • Inflammation
  • TAK1

Background

Transforming growth factor (TGF)-β-activated kinase 1 (TAK1) is a MAP3 kinase, upstream of several pathways that are involved in cerebral ischemic injury [1, 2]. TAK1 is activated by TGF-β, interleukin-1β, tumor necrosis factor-α, and other cytokines secreted after ischemic injury [3, 4]. Numerous studies have shown that site-specific ubiquitination and phosphorylation of TAK1 results in its activation [57]. TAK1 activation, in turn, induces the production of pro-inflammatory cytokines, chemokines, and activates immune cells that are known to play a detrimental role in stroke pathology [8, 9]. TAK1 is an essential gene and global deletion of TAK1 is embryonically lethal [10]. Growing evidence has shown that TAK1 is activated in neonatal hypoxia-ischemia, in in vitro models of oxygen-glucose deprivation, and after middle cerebral artery occlusion (MCAo), where it was demonstrated to aggravate injury [1, 2, 11]. Pharmacological inhibition of TAK1 reduces ischemic damage in a transient focal ischemia model [1, 2]. TAK1 is essential for protection against cytokine-induced cell death [12] and exerts anti-necrotic and antitumor activity [13]. Conditional tissue and hematopoietic-specific TAK1 ablation resulted in spontaneous tissue death [1416] and apoptosis in a variety of cell types [1719] but a recent study in which TAK1 was deleted from the alveolar macrophages and lung fibroblasts demonstrated attenuation of both inflammation and fibrosis in an experimental model of pneumoconiosis [20]. Thus, it is increasingly recognized that TAK1 regulation and function occurs in a tissue- and cell-specific manner.

There is ample evidence that the inflammatory response to stroke contributes to injury [2123]. After ischemic stroke, there is an increase in monocyte and neutrophil release from the bone marrow and spleen [24, 25]. Stroke leads to blood-brain barrier compromise, microglial activation, and invasion of peripheral immune cells into the brain [26, 27]. Monocytes and neutrophils traffic to the brain secondary to increased expression of adhesion molecules, cytokines/chemokines, proteases, and reactive oxygen species production [28, 29]. TAK1 is ubiquitously expressed on many cell types including macrophages, neutrophils [17, 3032], T cells [18, 33], B cells [19, 34], epidermal [14, 15], and intestinal epithelial cells [35]. Microglial-specific deletion of TAK1 reduced disease severity and immune cell infiltration in an experimental autoimmune encephalomyelitis model by inhibiting NFκB, JNK, and ERK1/2 signaling and dampening the inflammatory immune responses [36], suggesting a detrimental role of TAK1 in CNS inflammation. Hence, inhibition of TAK1 activation could be a potential neuroprotective strategy. However, a fundamental question remains: is myeloid TAK1 a key regulator of brain inflammation and its subsequent inactivation beneficial in the ischemic stroke? We hypothesized that myeloid TAK1 is a major contributor to cerebral ischemic damage as these cells aggressively infiltrate the brain and are involved in the evolution of brain injury. Conditional deletion of TAK1 in myeloid cells resulted in significant reduction of infiltrating monocytes into the brain and improved functional and infarct outcomes after ischemic stroke in mice.

Methods

Animals

TAK1fl/fl mice (a gift from Dr. Wang at University of Texas MD Anderson Cancer Center) were crossed with lysozyme M-Cre (LyzMCre) mice (Jackson Laboratory) to obtain TAK1ΔM mice in the C57BL/6 background. Young adult male mice (7–8 weeks) of age were group housed in the pathogen-free housing and had access to food and water ad libitum. Our pilot experiments showed no difference in the splenic immune cell composition between TAK1fl/+ LysM cre/+ and wild-type (WT) sham and MCAo cohorts. Thus, we used WT littermates as an experimental control group for further studies. All procedures were performed in accordance with NIH guidelines for the care and use of laboratory animals and were approved by the Institutional Animal care and use committee of the University of Texas Health Science Center.

Transient stroke model

Transient cerebral ischemia was induced by 90 min of reversible middle cerebral artery occlusion (MCAO as previously described [37]. Rectal temperatures were maintained at approximately 37 °C during surgery and ischemia with an automated temperature control feedback system. A midline ventral neck incision was made, and unilateral MCAO was performed by inserting a 6.0 Doccol monofilament (Doccol Corp, Redlands, CA, USA) into the right internal carotid. Cerebral blood flow (CBF) was measured by Laser Doppler flowmetry (Moor Instruments Ltd., Devor, England). CBF was measured before ischemia, during ischemia, and at the time of reperfusion. Following reperfusion, mice were sacrificed at day 3 after stroke. Sham controls were subjected to same procedure except the suture was not introduced into the internal carotid artery. Animals were randomly assigned into the stroke and sham surgery groups. For the 7-day outcome studies, mice were subjected to 60 min of ischemia followed by reperfusion.

Functional testing

Neurological deficit scores (NDS) were assessed at 3 and 7 days after a stroke on a four-point scale as described previously [38]. Corner testing (sensorimotor) and open field were performed at 3 and 7 days after stroke as described previously [39].

Tissue harvesting

Mice were euthanized day 3 post-ischemia. Mice were transcardially perfused with 60 mL of cold, sterile PBS. The olfactory bulb, brainstem, and cerebellum were removed. The brain was then divided along the interhemispheric fissure into two hemispheres and subsequently rinsed with PBS to remove adherent cells.

Flow cytometry

Spleens were removed and processed by mechanical disruption on a 70 μm filter screen. Red blood cell lysis was achieved by three consecutive 5–10 min incubations with Tris-ammonium chloride (Stem Cell Technologies). The ipsilateral hemisphere was placed in RPMI (Lonza) medium and mechanically and enzymatically digested in collagenase/dispase (1 mg/mL) and DNAse (10 mg/mL; both Roche Diagnostics). The cell suspension was filtered through a 70 μm mesh filter. Leukocytes were harvested from the interphase of a 70%/30% Percoll gradient. Spleen and brain leukocytes were washed with 1X PBS and blocked with mouse Fc Block (eBioscience, 1 μl/50 μl) prior to staining with primary antibody-conjugated fluorophores (CD45-AF700, CD11b-APC-eF780, Ly6G-FITC, Ly6C-APC, and CD49D-PE were purchased from eBioscience). For live/dead discrimination, a fixable viability dye was used (THERMOFISCHER SCIENTIFIC). Data were acquired on CytoFLEX cytometer (BECKMAN COULTER) and analyzed by FlowJo (TREESTAR INC.). Cell-specific fluorescence minus one controls were used to confirm individual antibody specificity. In spleen, monocytes and neutrophils were identified as (CD45+CD11b+Ly6C+ Ly6G) and (CD45+CD11b+Ly6C Ly6G+) respectively. T cells were identified by (CD45+CD11bCD3+) and B cells by (CD45+CD11bCD19+). In the brain, peripheral monocytes (Ly6C+), neutrophils (Ly6G+) were gated on CD45hi CD11b+, whereas peripheral lymphoid cells were gated on CD45hi CD11b population Additional file 1.

TTC and cresyl violet staining

Two cohorts of mice were examined that were euthanized at day 3 and 7 post-ischemia. For TTC staining, the animals were euthanized; brains were harvested and stored at − 80 °C for 4 min to slightly harden the tissue. Five, 2 mm coronal sections were cut from the olfactory bulb to the cerebellum and then stained with 1.5% TTC (SIGMA, St. Louise, MO). Slices were formalin-fixed (4%) and then digitalized for assessing infarct area using Sigma Scan Pro software as previously described [40]. The final infarct area is presented as percentage area (percentage of contralateral structures with correction for edema). For cresyl violet (CV) staining, animals were euthanized on day 7 after ischemia as described previously [41]. The infarct area of each brain was measured by an investigator blinded to the surgical groups, using image analysis software (Sigmascan Pro 5).

Naïve wild-type and TAK1ΔM (n = 3) mice were anesthetized and perfused with cold sterile PBS followed by 4% paraformaldehyde. A volume of 2 mL India ink (Sigma) and ferrous sulfate (1% in 20% India ink in PBS) was injected through the left ventricle. The animals were decapitated and brains were harvested with a circle of intact Willis. The brains were placed in 10% formalin overnight at 4 °C and examined for large vessel anatomy.

Statistical analysis

Data is expressed as mean ± standard errors of mean (SEM) except for NDS, which was presented as median (interquartile range). A two-sample t test or Wilcoxon rank-sum test was used to compare variables between different groups (Figs. 1a–d and 5a–d). Two-way ANOVA followed by post-hoc test adjusted by Tukey method was used (Figs 2, 3, and 4). Statistical significance was set at p < 0.05. All statistical analyses were performed using GraphPad Prism 7.
Fig. 1
Fig. 1

Deletion of TAK1 from myeloid cells resulted in reduced infarct and improved functional outcomes at day 3 post stroke. a TAK1ΔM mice had reduced neurological deficit scores (NDS). b Decreased turning bias on the corner test. c Increased locomotor activity. d Decreased infarct area at day 3 post stroke. Data is presented as Mean ± SEM, n = 6–8; *p < 0.05, **p < 0.01 (Two-sample t test or Wilcoxon rank-sum test)

Fig. 2
Fig. 2

Increase in splenic monocytes and decrease in CD3+ T and CD19+ B cells in TAK1ΔM mice. a Frequency of live cells in sham and MCAo groups. b Increase in splenic monocytes. c Increase splenic neutrophils after deletion of TAK1 from myeloid cells. d Decline in splenic CD3+ T cells and e CD19+ B cells in TAK1ΔM mice. Data is presented as mean ± SEM, n = 3–5; *p < 0.05, **p < 0.01 (two-way ANOVA followed by post-hoc Tukey)

Fig. 3
Fig. 3

Decrease in brain-infiltrating immune cells in the TAK1ΔM mice after stroke. a Decrease in infiltrating CD45hi immune cells. b Decline in infiltrating myeloid cells. c No difference in infiltrating lymphoid cells. d Decrease in monocyte counts. e No difference in the infiltrating neutrophils after stroke in TAK1ΔM mice MCAo mice at day 3. f No difference in microglia counts after stroke was seen in TAK1ΔM mice MCAo. g Representative flow plots showing infiltrating CD45hi cells in the brain. Data is presented as mean ± SEM, n = 3–5; *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA followed by post-hoc Tukey)

Fig. 4
Fig. 4

Decrease in splenic CD49d+ monocytes and decline in brain monocyte infiltration in TAK1ΔM mice after stroke. a Decrease in the frequency of CD49d+splenic monocytes. b Decrease in the CD49d MFI on splenic monocytes. c Decrease in frequency of CD49d+ monocyte in the brain of TAK1ΔM MCAo mice. d Increase in the frequency of splenic CD49d+ neutrophils. e No difference in the frequency of brain CD49d+ neutrophils after MCAo. f Representative flow plots showing CD49d gating on monocytes. Data is presented as mean ± SEM, n = 3–5; *p < 0.05, **p < 0.01, ***p < 0.001 (two-way ANOVA followed by post-hoc Tukey)

Results

No difference in cerebral large vessel anatomy, cerebral blood flow, and body temperatures between WT and TAK1 ΔM mice

No difference in the cerebral large vessel anatomy was observed between the WT and TAK1 ΔM mice (Additional file 2: Figure S2: A). Additionally, there was no difference in the cerebral blood flow between WT and TAK1 ΔM MCAo mice (Additional file 2: Figure S2: B). Furthermore, no difference in body temperature was observed between WT MCAo (36.50 ± 0.80) and TAK1 ΔM MCAo (36.65 ± 0.93) mice.

Deletion of myeloid TAK1 resulted in improved behavioral and infarct outcomes

To evaluate the role of myeloid TAK1 in cerebral ischemic injury, mice were subjected to 90 min of cerebral ischemia and behavioral assessments were done on day 3 post-stroke. The results of the Wilcoxon rank-sum test showed that the neurological deficit scores (NDS) were lower in the TAK1ΔM MCAo as compared to control TAK1 intact MCAo mice, though this did not reach statistical significance (p = 0.07, Fig. 1a). The Welch corrected t test results demonstrated a significant decline in the corner test scores in the TAK1 ΔM MCAo mice compared to the control MCAo group (p = 0.0036, Fig. 1b). In the open field task, total beam breaks were higher in the TAK1ΔM MCAo vs control MCAo group reflecting an increase in locomotor activity (p = 0.023, Fig. 1c). A significant reduction in cortical infarct (p = 0.003) and hemispheric (p = 0.005) infarct was seen. There was no difference (p = 0.49) in the striatal infarct between both the MCAo groups. These results demonstrate that myeloid TAK1 deletion protects against stroke and reduces behavioral deficits.

TAK1ΔM mice exhibited expansion of splenic myeloid populations and decreased lymphocytes

To investigate changes in the peripheral immune compartment, the spleen of the TAK1 ΔM and control mice was immunophenotyped at day 3 post-stroke. Previous studies have shown that cell type and tissue-specific TAK1 deletion increases cell death in multiple cells and tissues including hematopoietic cells, monocytes, epidermis, and intestinal epithelium [14, 32, 35, 42].

We observed no difference in the frequency of splenic live cells between control and TAK1ΔM shams and MCAo groups (Fig. 2a). However, there was significant effect of myeloid TAK1 deletion on frequency of monocytes (F (1, 12) = 14.3, p = 0.0026) and neutrophils (F (1, 12) = 18.4, p = 0.0011). The splenic frequency of monocytes (Fig. 2b) and neutrophils (p = 0.024, Fig. 2c) was increased in the TAK1 ΔM sham mice likely reflecting extramedullary hematopoiesis, which has also been reported [17]. Additionally, a significant effect of myeloid TAK1 deletion was observed on frequency of T cells (F (1, 12) = 22.1, p = 0.0005) and B cells (F (1, 12) = 21.6, p = 0.0006). Deletion of myeloid TAK1 resulted in a decrease in the splenic T (p = 0.008, Fig. 2d) and B cell frequencies (p = 0.06, Fig. 2e), hence we observed an expansion in splenic myeloid compartment and decrease in lymphocytes.

Decrease in brain-infiltrating immune cells in TAK1 Δ M mice after stroke

Stroke led to an increase in CD45hi cells in the brain of both WT MCAo (p < 0.0001) and TAK1 ΔM MCAo mice (p = 0.01) as compared to their respective sham controls. CD45hi counts were significantly lower (p = 0.048) in the brains of TAK1ΔM MCAo as compared to WT MCAo mice (Fig. 3a). This was driven by a relatively selective decrease in myeloid infiltration after stroke as TAK1 ΔM mice had significantly less infiltration of myeloid cells (p = 0.018, Fig. 3b) as compared to WT MCAo mice. This was primarily due to a significant reduction in the number of monocytes (Fig. 3d), but not neutrophils (Fig. 3e), reflecting a monocyte-specific mechanism. A stroke-induced decrease in microglia counts was evident in both the MCAo groups at day 3 post stroke (Fig. 3f). No difference was observed in the infiltration of peripheral lymphoid cells between TAK1ΔM MCAo as compared to WT MCAo mice, suggesting that the reduction in infiltrating monocytes was not simply reflective of the reduced infarct in TAK1ΔM mice (Fig. 3c).

TAK1 loss in myeloid cells block monocyte extravasation into the brain

The spleen is highly innervated by the sympathetic nervous system. After a stroke, there is activation of a sympathetic nervous system that results in the involution of the spleen and transmigration of immune cells that correlates well with infarct size [4345]. To infiltrate the brain, circulating leukocytes utilize the CD49d and VCAM axis, an important mediator of immune cell entry after injury [4648]. A significant reduction (p = 0.006) in the frequency of splenic CD49d+ monocytes was seen in TAK1ΔM as compared to control sham mice Fig. 4a). Moreover, the mean fluorescence intensity (MFI) of CD49d on monocytes was significantly lower (p = 0.10) in the TAK1ΔM as compared to control sham mice (Fig. 4b). A significant decrease (p = 0.0044) in the frequency of splenic CD49d+ monocytes in the WT MCAo and TAK1ΔM MCAo (p = 0.210) was observed as compared to their respective shams (Fig. 4a). Additionally, a significant reduction on MFI was observed in WT MCAo (p = 0.009) as compared to WT sham. Moreover, TAK1ΔM MCAo has lower (p = 0.023) splenic CD49d MFI as compared to WT MCAo (Fig. 4b).

Subsequently, a stroke-driven increase in the brain CD49d+ monocyte numbers was observed in WT MCAo (p < 0.0001) and TAK1ΔM MCAo (0.022) as compared to their respective shams. Interestingly, TAK1ΔM MCAo had reduced frequency (p < 0.001) of CD49d+ monocytes as compared to WT MCAo mice. On the other hand, the frequency of splenic CD49d+ neutrophils was higher (p = 0.0013) in the TAK1 ΔM as compared to control sham mice reflecting an increased extravasation of neutrophils in the spleens of these mice (Fig. 4d). Additionally, there was no difference in splenic CD49+ neutrophils in the TAK1ΔM MCAo (p = 0.56) and WT MCAo (p = 0.75) compared to their respective shams. A stroke-induced increase in CD49d+ neutrophil frequency was observed in the brains of both TAK1ΔM and WT MCAo mice (Fig. 4e). However, no difference in CD49d+ neutrophils was seen between TAK1ΔM and WT stroke animals. These results suggested that TAK1 loss in myeloid cells selectively affected monocytes transmigration to the brain after stroke, but did not affect the neutrophil migration.

Smaller infarcts and improved functional outcomes in TAK1ΔM mice at day 7 post stroke

To evaluate functional outcomes and infarct size a week after injury, mice in both cohorts underwent a 60-min MCAo (Fig. 5). At day 7 after stroke, NDS and total beam breaks were not significantly different between the TAK1ΔM and control MCAo mice (p = 0.45, Fig. 5a, c), however, corner test scores were significantly lower (p = 0.033, Fig. 5b) in the TAK1ΔM MCAo as compared to WT MCAo mice, demonstrating a continued sensorimotor deficit in WT stroke mice that was ameliorated by myeloid TAK deletion. Additionally, TAK1ΔM MCAo mice had significantly smaller cortical (p = 0.002), striatal (p = 0.014), and hemispheric infarcts (p = 0.0008) as compared to WT MCAo animals (Fig. 5d).
Fig. 5
Fig. 5

Deletion of TAK1 from myeloid cells resulted in reduced infarct and improved functional outcomes at day 7 post stroke. a TAK1ΔM mice had lower neurological deficit scores. b TAK1ΔM mice had less turning bias in the corner test. c No differences were seen in locomotor activity. d Decreased infarcts were seen at day 7 post stroke. Data is presented as mean ± SEM, n = 8; *p < 0.05, **p < 0.01 (two-sample t test or Wilcoxon rank-sum test)

Discussion

This work demonstrates several novel findings which support our hypothesis that myeloid TAK1 is one of the key molecules essential for progression of cerebral injury in focal ischemic stroke. First, myeloid TAK1 knockout mice had smaller infarcts and improved functional outcomes at day 3 post-stroke. Secondly, myeloid TAK1ΔM mice had reduced infiltration of peripheral immune cells into the brain after stroke. Thirdly, there was a specific reduction in monocyte infiltration in the TAK1ΔM mice after stroke. Interestingly, there were fewer splenic CD49d+ monocytes in TAK1ΔM mice and a corresponding reduction in CD49d+ monocytes in the brains of TAK1ΔM mice after stroke that was associated with a reduction in injury (Fig. 6). Lastly, at day 7 post-stroke, TAK1ΔM MCAo mice had smaller infarcts and improved functional outcomes.
Fig. 6
Fig. 6

Proposed mechanism for reduced brain injury by myeloid TAK1 deletion. Loss of TAK1 in myeloid cells resulted in reduced CD49 integrin expression on splenic monocytes. After ischemia-reperfusion injury, attenuation of splenic monocytes egress from the spleen and recruitment of CD49d+ monocytes into the brain

TAK1 is a member of a MAP3 kinase family and is activated by many diverse inflammatory stimuli. Once activated TAK1 and its adaptor proteins, TAB2, TAB3, and NEMO are recruited and phosphorylate TAK1 and activate κB kinase (IKK). IKK activation induces proinflammatory cytokines, chemokines, and activation of immune cells. Conversely, TAK1 protects cells against cytokine-induced death by producing anti-apoptotic proteins [49]. Additionally, TAK1 can confer anti-necrotic and anti-carcinogenic effects and helps maintain tissue homeostasis [17, 49]. The inflammatory response plays an essential role in stroke pathology. After a stroke, the breakdown of the blood-brain barrier results in activation of immune cells locally, the release of pro-inflammatory cytokines, and expression of adhesion molecules, which leads to the recruitment of immune cells from the circulation [50]. Stroke profoundly affects the peripheral immune system and inhibition of peripheral inflammation may prove to be an attractive strategy for stroke treatment. TAK1 is an important target, which is strategically placed upstream of many inflammatory signaling pathways including MAPK/Jnk, MAPK/Erk, NFκB. Pharmacological inhibition of TAK1 reduces infarct damage but may have off-target effects and inhibitors have difficulty crossing the blood-brain barrier, which would be less of a concern if the beneficial effects of TAK1 inhibition are secondary to suppression of peripheral immune cell TAK1 activation.

We examined mice with myeloid deletion of TAK1 to delineate the in vivo function of TAK1 after ischemic stroke. In order to produce a conditional deletion of TAK1 in myeloid cells, we used the Cre-LoxP system, in which Cre expression is under lysozyme M promoter. This mouse line has been extensively used to induce Cre expression in macrophages, neutrophils, and microglia [17, 32, 5154]. Results from crossing LysM-Cre mice with reporter mice have shown 30–45% recombination in microglia [36, 55] and high recombination in peripheral monocytes and neutrophils. Animals with myeloid-specific TAK1 deletion were generated using the LysM-Cre mouse line. Deletion of TAK1 from neutrophils and monocyte/macrophages also microglia (Additional file 3: Figure S3), resulted in high circulating neutrophils, monocytes, and animals develop splenomegaly [17]. Tissue-specific deletion of TAK1 caused cell death in tissues including epidermis, intestinal epithelium, hepatocytes, and osteoblasts [32, 42]. Interestingly, myeloid-specific TAK1 deletion did not induce cell death in our study, a finding also seen by others [17, 30]. A previous study by Goldmann et al. [36] has shown that conditional deletion of TAK1 on microglia (using a cx3cr1 model) resulted in reduced autoimmune inflammation and axonal and myelin damage in experimental autoimmune encephalomyelitis model, demonstrating a role of microglial TAK1 in neuroinflammation. After a stroke, microglia are activated and release proinflammatory cytokines and leukocyte adhesion molecules. By binding to adhesion molecules, peripheral immune cells including neutrophils, monocytes, and lymphocytes are recruited to the site of injury. These infiltrated immune cells then release proinflammatory cytokines and further aggravate the cerebral injury [44, 45, 56]. TAK1 is important for myeloid cell function and is required for IKK and JNK activation which results in the production of pro-inflammatory cytokines [17]. After a stroke, the myeloid-specific TAK1 deleted animals had less infiltrated immune cells which were a consequence of reduced monocyte counts in these mice. No difference in the neutrophil counts after stroke was evident reflecting a monocytes-specific role. CD49d is expressed on the surface of all leukocytes including monocytes and neutrophils and is responsible for tethering, rolling, and firm adhesion to the blood vessels [57, 58]. Leukocytes use the CD49d and VCAM-1 axis to transmigrate to the site of brain injury [57, 58]. In the myeloid-specific TAK1 deleted mice, there were reduced CD49d+ monocytes reflecting less extravasation of peripheral monocytes after stroke. This decline in CD49d positivity was monocyte specific as no difference in CD49d+ neutrophils was observed after stroke in both the cohorts. Previous studies have shown that the monocytes from the myeloid TAK1-depleted animals have reduced stimulus-induced activation of IKK and JNK [17], which might suggest the reduced production of proinflammatory cytokines, though this needs to be further validated. Finally, we investigated whether the benefit of TAK1ΔM deletion was sustained at a second, later time point after the peak of immune cell infiltration. Both behavioral outcomes and infarct size were significantly better in TAK1ΔM MCAo animals reflecting that myeloid TAK1 deletion was still protective at day 7 post-ischemia.

Our findings suggest that myeloid TAK1 deletion results in neuroprotection, similar to what was seen with global pharmacological inhibition. However, this study has several limitations. First, we investigated the effect of myeloid TAK1 deletion at relatively acute time points after stroke, so the role of TAK1 in chronic repair and recovery remains to be explored. Secondly, we did not include female and older animals as this initial study was designed to explore if there was any role of myeloid TAK1 in acute stroke outcomes. Finally, as TAK1 was deleted from all myeloid cells, we cannot specifically delineate the role of central and peripheral TAK1 activation in stroke injury. Finally, constitutively deleting TAK1 from myeloid cells resulted in an increase in frequency of peripheral monocytes and neutrophil, though we did not evaluate the functional consequences of these changes, which could have affected aspects of monocyte and neutrophil physiology, hence the use of an inducible TAK1 deletion model would strengthen our findings and will be developed for use in future studies.

Conclusions

In conclusion, we found that myeloid-specific TAK1 deletion reduced infarct injury and improved functional outcomes after stroke. The mechanism for the reduced cerebral damage in this group appears to be secondary to a specific and selective decrease in monocyte infiltration into the ischemic brain. Selective inhibition of TAK1 in peripheral myeloid cells could be a useful strategy for stroke therapy.

Declarations

Acknowledgments

The authors will like to thank Ms. Yan Xu for maintaining the transgenic animal colony.

Funding

This work was supported by NIH NINDS R21 NSO88969

Availability of data and materials

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

AC conceived, performed, and drafted the manuscript. JH, AAM, ECK, PG, and RMR assisted in the FACS experiments. AP assisted with stroke surgeries. LDM oversaw the experiments and critically reviewed the manuscript. All authors have read and approved the manuscript.

Ethics approval

All procedures were performed in accordance with NIH guidelines for the care and use of laboratory animals and were approved by the Institutional Animal care and use committee of the University of Texas Health Science Center.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Neurology, University of Texas McGovern Medical School at Houston, Houston, TX 77030, USA
(2)
Department of Anesthesiology and Center for Shock, Trauma and Anesthesiology Research (STAR), University of Maryland School of Medicine, Baltimore, MD 21201, USA
(3)
Memorial Hermann Hospital-Texas Medical Center, Houston, TX 77030, USA

References

  1. Neubert M, Ridder DA, Bargiotas P, Akira S, Schwaninger M. Acute inhibition of TAK1 protects against neuronal death in cerebral ischemia. Cell Death Differ. 2011;18:1521–30.View ArticlePubMedPubMed CentralGoogle Scholar
  2. White BJ, Tarabishy S, Venna VR, Manwani B, Benashski S, McCullough LD, Li J. Protection from cerebral ischemia by inhibition of TGFbeta-activated kinase. Exp Neurol. 2012;237:238–45.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Ridder DA, Schwaninger M. NF-kappaB signaling in cerebral ischemia. Neuroscience. 2009;158:995–1006.View ArticlePubMedGoogle Scholar
  4. Sakurai H. Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol Sci. 2012;33:522–30.View ArticlePubMedGoogle Scholar
  5. Ajibade AA, Wang HY, Wang RF. Cell type-specific function of TAK1 in innate immune signaling. Trends Immunol. 2013;34:307–16.View ArticlePubMedGoogle Scholar
  6. Singhirunnusorn P, Suzuki S, Kawasaki N, Saiki I, Sakurai H. Critical roles of threonine 187 phosphorylation in cellular stress-induced rapid and transient activation of transforming growth factor-beta-activated kinase 1 (TAK1) in a signaling complex containing TAK1-binding protein TAB1 and TAB2. J Biol Chem. 2005;280:7359–68.View ArticlePubMedGoogle Scholar
  7. Scholz R, Sidler CL, Thali RF, Winssinger N, Cheung PC, Neumann D. Autoactivation of transforming growth factor beta-activated kinase 1 is a sequential bimolecular process. J Biol Chem. 2010;285:25753–66.View ArticlePubMedPubMed CentralGoogle Scholar
  8. Zhang J, Lei T, Chen X, Peng Y, Long H, Zhou L, Huang J, Chen Z, Long Q, Yang Z. Resistin up-regulates COX-2 expression via TAK1-IKK-NF-kappaB signaling pathway. Inflammation. 2010;33:25–33.View ArticlePubMedGoogle Scholar
  9. Kumar M, Makonchuk DY, Li H, Mittal A, Kumar A. TNF-like weak inducer of apoptosis (TWEAK) activates proinflammatory signaling pathways and gene expression through the activation of TGF-beta-activated kinase 1. J Immunol. 2009;182:2439–48.View ArticlePubMedPubMed CentralGoogle Scholar
  10. Jadrich JL, O'Connor MB, Coucouvanis E. The TGF beta activated kinase TAK1 regulates vascular development in vivo. Development. 2006;133:1529–41.View ArticlePubMedGoogle Scholar
  11. Nijboer CH, Heijnen CJ, Groenendaal F, van Bel F, Kavelaars A. Alternate pathways preserve tumor necrosis factor-alpha production after nuclear factor-kappaB inhibition in neonatal cerebral hypoxia-ischemia. Stroke. 2009;40:3362–8.View ArticlePubMedGoogle Scholar
  12. Karin M, Gallagher E. TNFR signaling: ubiquitin-conjugated TRAFfic signals control stop-and-go for MAPK signaling complexes. Immunol Rev. 2009;228:225–40.View ArticlePubMedGoogle Scholar
  13. Bettermann K, Vucur M, Haybaeck J, Koppe C, Janssen J, Heymann F, Weber A, Weiskirchen R, Liedtke C, Gassler N, et al. TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. Cancer Cell. 2010;17:481–96.View ArticlePubMedGoogle Scholar
  14. Omori E, Matsumoto K, Sanjo H, Sato S, Akira S, Smart RC, Ninomiya-Tsuji J. TAK1 is a master regulator of epidermal homeostasis involving skin inflammation and apoptosis. J Biol Chem. 2006;281:19610–7.View ArticlePubMedPubMed CentralGoogle Scholar
  15. Sayama K, Hanakawa Y, Nagai H, Shirakata Y, Dai X, Hirakawa S, Tokumaru S, Tohyama M, Yang L, Sato S, et al. Transforming growth factor-beta-activated kinase 1 is essential for differentiation and the prevention of apoptosis in epidermis. J Biol Chem. 2006;281:22013–20.View ArticlePubMedGoogle Scholar
  16. Yang L, Inokuchi S, Roh YS, Song J, Loomba R, Park EJ, Seki E. Transforming growth factor-beta signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1. Gastroenterology. 2013;144:1042–54. e1044View ArticlePubMedPubMed CentralGoogle Scholar
  17. Lamothe B, Lai Y, Hur L, Orozco NM, Wang J, Campos AD, Xie M, Schneider MD, Lockworth CR, Jakacky J, et al. Deletion of TAK1 in the myeloid lineage results in the spontaneous development of myelomonocytic leukemia in mice. PLoS One. 2012;7:e51228.View ArticlePubMedPubMed CentralGoogle Scholar
  18. Wan YY, Chi H, Xie M, Schneider MD, Flavell RA. The kinase TAK1 integrates antigen and cytokine receptor signaling for T cell development, survival and function. Nat Immunol. 2006;7:851–8.View ArticlePubMedGoogle Scholar
  19. Schuman J, Chen Y, Podd A, Yu M, Liu HH, Wen R, Chen ZJ, Wang D. A critical role of TAK1 in B-cell receptor-mediated nuclear factor kappaB activation. Blood. 2009;113:4566–74.View ArticlePubMedPubMed CentralGoogle Scholar
  20. Li J, Liang C, Zhang ZK, Pan X, Peng S, Lee WS, Lu A, Lin Z, Zhang G, Leung WN, Zhang BT. TAK1 inhibition attenuates both inflammation and fibrosis in experimental pneumoconiosis. Cell Discovery. 2017;3:17023.View ArticlePubMedPubMed CentralGoogle Scholar
  21. Turtzo LC, Li J, Persky R, Benashski S, Weston G, Bucala R, Venna VR, McCullough LD. Deletion of macrophage migration inhibitory factor worsens stroke outcome in female mice. Neurobiol Dis. 2013;54:421–31.View ArticlePubMedPubMed CentralGoogle Scholar
  22. Tian Y, Stamova B, Jickling GC, Liu D, Ander BP, Bushnell C, Zhan X, Davis RR, Verro P, Pevec WC, et al. Effects of gender on gene expression in the blood of ischemic stroke patients. J Cereb Blood Flow Metab. 2012;32:780–91.View ArticlePubMedGoogle Scholar
  23. Gill D, Veltkamp R. Dynamics of T cell responses after stroke. Curr Opin Pharmacol. 2016;26:26–32.View ArticlePubMedGoogle Scholar
  24. Benakis C, Garcia-Bonilla L, Iadecola C, Anrather J. The role of microglia and myeloid immune cells in acute cerebral ischemia. Front Cell Neurosci. 2014;8:461.PubMedGoogle Scholar
  25. Tsai NW, Chang WN, Shaw CF, Jan CR, Lu CH. Leucocyte apoptosis in patients with acute ischaemic stroke. Clin Exp Pharmacol Physiol. 2010;37:884–8.View ArticlePubMedGoogle Scholar
  26. Jin R, Yang G, Li G. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol. 2010;87:779–89.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Neumann H, Kotter MR, Franklin RJ. Debris clearance by microglia: an essential link between degeneration and regeneration. Brain. 2009;132:288–95.View ArticlePubMedGoogle Scholar
  28. Tsai NW, Chang WN, Shaw CF, Jan CR, Huang CR, Chen SD, Chuang YC, Lee LH, Lu CH. The value of leukocyte adhesion molecules in patients after ischemic stroke. J Neurol. 2009;256:1296–302.View ArticlePubMedGoogle Scholar
  29. Cojocaru IM, Cojocaru M, Burcin C. Evaluation of granulocyte elastase as a sensitive diagnostic parameter of inflammation in first ischemic stroke. Rom J Intern Med. 2006;44:317–21.PubMedGoogle Scholar
  30. Ajibade AA, Wang Q, Cui J, Zou J, Xia X, Wang M, Tong Y, Hui W, Liu D, Su B, et al. TAK1 negatively regulates NF-kappaB and p38 MAP kinase activation in Gr-1+CD11b+ neutrophils. Immunity. 2012;36:43–54.View ArticlePubMedPubMed CentralGoogle Scholar
  31. Eftychi C, Karagianni N, Alexiou M, Apostolaki M, Kollias G. Myeloid TAKI [corrected] acts as a negative regulator of the LPS response and mediates resistance to endotoxemia. PLoS One. 2012;7:e31550.View ArticlePubMedPubMed CentralGoogle Scholar
  32. Lamothe B, Lai Y, Xie M, Schneider MD, Darnay BG. TAK1 is essential for osteoclast differentiation and is an important modulator of cell death by apoptosis and necroptosis. Mol Cell Biol. 2013;33:582–95.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Liu HH, Xie M, Schneider MD, Chen ZJ. Essential role of TAK1 in thymocyte development and activation. Proc Natl Acad Sci U S A. 2006;103:11677–82.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Sato S, Sanjo H, Takeda K, Ninomiya-Tsuji J, Yamamoto M, Kawai T, Matsumoto K, Takeuchi O, Akira S. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol. 2005;6:1087–95.View ArticlePubMedGoogle Scholar
  35. Kajino-Sakamoto R, Inagaki M, Lippert E, Akira S, Robine S, Matsumoto K, Jobin C, Ninomiya-Tsuji J. Enterocyte-derived TAK1 signaling prevents epithelium apoptosis and the development of ileitis and colitis. J Immunol. 2008;181:1143–52.View ArticlePubMedPubMed CentralGoogle Scholar
  36. Goldmann T, Wieghofer P, Muller PF, Wolf Y, Varol D, Yona S, Brendecke SM, Kierdorf K, Staszewski O, Datta M, et al. A new type of microglia gene targeting shows TAK1 to be pivotal in CNS autoimmune inflammation. Nat Neurosci. 2013;16:1618–26.View ArticlePubMedGoogle Scholar
  37. McCullough LD, Zeng Z, Li H, Landree LE, McFadden J, Ronnett GV. Pharmacological inhibition of AMP-activated protein kinase provides neuroprotection in stroke. J Biol Chem. 2005;280:20493–502.View ArticlePubMedGoogle Scholar
  38. McCullough LD, Tarabishy S, Liu L, Benashski S, Xu Y, Ribar T, Means A, Li J. Inhibition of calcium/calmodulin-dependent protein kinase kinase beta and calcium/calmodulin-dependent protein kinase IV is detrimental in cerebral ischemia. Stroke. 2013;44:2559–66.View ArticlePubMedGoogle Scholar
  39. Li X, Blizzard KK, Zeng Z, DeVries AC, Hurn PD, McCullough LD. Chronic behavioral testing after focal ischemia in the mouse: functional recovery and the effects of gender. Exp Neurol. 2004;187:94–104.View ArticlePubMedGoogle Scholar
  40. Venna VR, Weston G, Benashski SE, Tarabishy S, Liu F, Li J, Conti LH, McCullough LD. NF-kappaB contributes to the detrimental effects of social isolation after experimental stroke. Acta Neuropathol. 2012;124:425–38.View ArticlePubMedPubMed CentralGoogle Scholar
  41. Manwani B, Friedler B, Verma R, Venna VR, McCullough LD, Liu F. Perfusion of ischemic brain in young and aged animals: a laser speckle flowmetry study. Stroke. 2014;45:571–8.View ArticlePubMedGoogle Scholar
  42. Sakamachi Y, Morioka S, Mihaly SR, Takaesu G, Foley JF, Fessler MB, Ninomiya-Tsuji J. TAK1 regulates resident macrophages by protecting lysosomal integrity. Cell Death Dis. 2017;8:e2598.View ArticlePubMedPubMed CentralGoogle Scholar
  43. Pennypacker KR, Offner H. The role of the spleen in ischemic stroke. J Cereb Blood Flow Metab. 2015;35:186–7.View ArticlePubMedGoogle Scholar
  44. Seifert HA, Hall AA, Chapman CB, Collier LA, Willing AE, Pennypacker KR. A transient decrease in spleen size following stroke corresponds to splenocyte release into systemic circulation. J NeuroImmune Pharmacol. 2012;7:1017–24.View ArticlePubMedPubMed CentralGoogle Scholar
  45. Chauhan A, Al Mamun A, Spiegel G, Harris N, Zhu L, McCullough LD. Splenectomy protects aged mice from injury after experimental stroke. Neurobiol Aging. 2017;61:102–11.View ArticlePubMedGoogle Scholar
  46. Hammond MD, Ambler WG, Ai Y. Sansing LH: alpha4 integrin is a regulator of leukocyte recruitment after experimental intracerebral hemorrhage. Stroke. 2014;45:2485–7.View ArticlePubMedPubMed CentralGoogle Scholar
  47. Young KG, Maclean S, Dudani R, Krishnan L, Sad S. CD8+ T cells primed in the periphery provide time-bound immune-surveillance to the central nervous system. J Immunol. 2011;187:1192–200.View ArticlePubMedPubMed CentralGoogle Scholar
  48. Sa Q, Ochiai E, Sengoku T, Wilson ME, Brogli M, Crutcher S, Michie SA, Xu B, Payne L, Wang X, Suzuki Y. VCAM-1/alpha4beta1 integrin interaction is crucial for prompt recruitment of immune T cells into the brain during the early stage of reactivation of chronic infection with toxoplasma gondii to prevent toxoplasmic encephalitis. Infect Immun. 2014;82:2826–39.View ArticlePubMedPubMed CentralGoogle Scholar
  49. Ridder DA, Schwaninger M. TAK1 inhibition for treatment of cerebral ischemia. Exp Neurol. 2013;239:68–72.View ArticlePubMedGoogle Scholar
  50. Prass K, Meisel C, Hoflich C, Braun J, Halle E, Wolf T, Ruscher K, Victorov IV, Priller J, Dirnagl U, et al. Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J Exp Med. 2003;198:725–36.View ArticlePubMedPubMed CentralGoogle Scholar
  51. Cho IH, Hong J, Suh EC, Kim JH, Lee H, Lee JE, Lee S, Kim CH, Kim DW, Jo EK, et al. Role of microglial IKKbeta in kainic acid-induced hippocampal neuronal cell death. Brain. 2008;131:3019–33.View ArticlePubMedPubMed CentralGoogle Scholar
  52. Derecki NC, Cronk JC, Lu Z, Xu E, Abbott SB, Guyenet PG, Kipnis J. Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature. 2012;484:105–9.View ArticlePubMedPubMed CentralGoogle Scholar
  53. Kaindl AM, Degos V, Peineau S, Gouadon E, Chhor V, Loron G, Le Charpentier T, Josserand J, Ali C, Vivien D, et al. Activation of microglial N-methyl-D-aspartate receptors triggers inflammation and neuronal cell death in the developing and mature brain. Ann Neurol. 2012;72:536–49.View ArticlePubMedGoogle Scholar
  54. Pulido-Salgado M, Vidal-Taboada JM, Garcia Diaz-Barriga G, Serratosa J, Valente T, Castillo P, Matalonga J, Straccia M, Canals JM, Valledor A, et al. Myeloid C/EBPbeta deficiency reshapes microglial gene expression and is protective in experimental autoimmune encephalomyelitis. J Neuroinflammation. 2017;14:54.View ArticlePubMedPubMed CentralGoogle Scholar
  55. Hucke S, Flossdorf J, Grutzke B, Dunay IR, Frenzel K, Jungverdorben J, Linnartz B, Mack M, Peitz M, Brustle O, et al. Licensing of myeloid cells promotes central nervous system autoimmunity and is controlled by peroxisome proliferator-activated receptor gamma. Brain. 2012;135:1586–605.View ArticlePubMedGoogle Scholar
  56. Offner H, Subramanian S, Parker SM, Afentoulis ME, Vandenbark AA, Hurn PD. Experimental stroke induces massive, rapid activation of the peripheral immune system. J Cereb Blood Flow Metab. 2006;26:654–65.View ArticlePubMedGoogle Scholar
  57. Neumann J, Riek-Burchardt M, Herz J, Doeppner TR, Konig R, Hutten H, Etemire E, Mann L, Klingberg A, Fischer T, et al. Very-late-antigen-4 (VLA-4)-mediated brain invasion by neutrophils leads to interactions with microglia, increased ischemic injury and impaired behavior in experimental stroke. Acta Neuropathol. 2015;129:259–77.View ArticlePubMedGoogle Scholar
  58. Takeshita Y, Ransohoff RM. Inflammatory cell trafficking across the blood-brain barrier: chemokine regulation and in vitro models. Immunol Rev. 2012;248:228–39.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

Advertisement